| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | -0.0075 | 0.9 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |